Valentine’s Day deal is true love for Nektar and Bristol-Myers

A new deal between Bristol-Myers Squibb Co. and Nektar Therapeutics came up candy hearts and roses for investors, sending Nektar shares up 12.5% and Bristol-Myers shares up 2.8% in heavy Wednesday trade.

The deal is structured in a relatively complex way, effectively serving to limit Bristol-Myers’ BMY, +2.69% upfront payments while giving the drugmaker a cut of net profits and losses for Nektar’s NKTR, +10.31%  promising immuno-oncology drug NKTR-214, which the two companies will jointly develop and commercialize.

Under the agreement, Bristol-Myers will pay $1 billion in cash plus $850 million in Nektar stock upfront and get a 35% cut of net profits and losses for NKTR-214. Nektar will also be eligible for up to $1.78 billion in various milestone payments.

Bristol-Myers “got a very good deal structure on this [immuno-oncology] program,” said EvercoreISI analyst Umer Raffat. “BMY was able to get 35% economics, and yet not bet $16B upfront.”

Related: Nektar Therapeutics’ stock rockets toward near 17-year high after upbeat trial data and Eli Lilly will co-develop autoimmune disease therapy under $150 million deal with Nektar

The deal, which is expected to close in the second quarter, aims to test NKTR-214 in trials in more than 20 indications in nine tumor types.

The companies will split costs for combination regimens depending on product ownership, giving as examples NKTR-214 in combination with Bristol-Myers’ Opdivo and NKTR-214 in combination with Bristol-Myers’ Opdivo and Yervoy.

Both Opdivo and Yervoy are immuno-oncology therapies, a new category of drugs which harness a patient’s immune system to fight cancer,

Pairing immuno-oncology drugs has become an important but still relatively unproven trend for drugmakers, with hundreds of ongoing and completed trials.

Read: Cancer drug prices could double or triple thanks to this popular but unproven drug trend

Bristol-Myers and Nektar’s latest deal follows that pattern, and “enables BMY to remain the company with most IO-IO combinations in Ph 3,” Raffat said, adding, “I like this addition to BMY portfolio.”

Bristol-Myers expects the deal will negatively affect 2018 adjusted earnings-per-share by about 2 cents and adjusted 2019 EPS by 10 cents.

Nektar shares initially declined nearly 5% in Wednesday morning trade before turning upward. Shares have surged 115.8% over the last three months, compared with a 7.3% rise in Bristol-Myers shares and a 4.5% rise in the S&P 500 SPX, +1.32%

Filed in: Top News Tags: 

You might like:

The Wall Street Journal: Stacey Abrams eyes history after win in Georgia gubernatorial primary The Wall Street Journal: Stacey Abrams eyes history after win in Georgia gubernatorial primary
Asia Markets: Nikkei leads Asian-market losses as investors’ geopolitical worries grow Asia Markets: Nikkei leads Asian-market losses as investors’ geopolitical worries grow
The Wall Street Journal: Walmart to buy SoftBank’s stake in India’s Flipkart The Wall Street Journal: Walmart to buy SoftBank’s stake in India’s Flipkart
The Wall Street Journal: Wynn Resorts’ executive compensation plan rejected by shareholders The Wall Street Journal: Wynn Resorts’ executive compensation plan rejected by shareholders
Trump hints at more tax cuts to be unveiled before November Trump hints at more tax cuts to be unveiled before November
One New York couple asked a court to help them evict their 30-year-old son One New York couple asked a court to help them evict their 30-year-old son
The Wall Street Journal: Israeli firm partnered with Cambridge Analytica to win U.S. government contracts The Wall Street Journal: Israeli firm partnered with Cambridge Analytica to win U.S. government contracts
Key Words: Is voting in 2018 really as important as in 2016? Trump’s not so sure Key Words: Is voting in 2018 really as important as in 2016? Trump’s not so sure

Leave a Reply

Submit Comment
© 2018 Stock Investors News. All rights reserved. XHTML / CSS Valid.